The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.

The practice of routinely maintaining PIVC access has not only benefits but also risks. It’s due for a mindset shift, with ...

One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or ...

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 ...

Rapid treatment with CeleCor Therapeutics' investigational heart-attack drug, zalunfiban, resulted in higher levels of blood flow to the heart and an approximately 21% reduction in a patient's risk of ...

Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are ...

The landscape of coronary and pulmonary vascular medicine is undergoing a paradigm shift, fueled by breakthroughs in molecular biology, imaging, and ...

DES, adding clopidogrel in the chronic phase of coronary disease had no ischemic benefit and increased bleeding.

Additionally, Judith S. Hochman, MD, senior associate dean for clinical sciences, founding director of the Cardiovascular ...

How Metamaterial Design Could Give Interventional Cardiologists Finer Control in Complex Heart Surgeries Coronary artery disease afflicts 18 million ...

For optimal 1-year results, in patients with prior coronary artery bypass grafting who need percutaneous coronary ...

View the full release here: "With a similar safety profile, OPN can be a feasible and faster alternative to IVL." Dr. M. Bossard, Senior Physician at Luzerner Kantonsspital, Switzerland A total of ...